Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...

Panelists discuss how managing oral therapy toxicities requires preemptive planning, multidisciplinary team involvement, patient and family education, and close monitoring for drug interactions and ...

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...

Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

Combining the menin inhibitor, revumenib, plus the hypothemylating agent, ASTX727, and venetoclax achieved an overall response rate of 82% in 33 adult and pediatric patients with relapsed or ...

Researchers discovered a promising leukemia drug breakthrough that could help patients overcome treatment resistance, ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA ...